HOUSTON , March 08, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that company management will participate at the following upcoming investor conference: Event: Cowen and Company 39th Annual Health Care Conference Presentation Date &
HOUSTON , March 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company focused on developing innovative therapies that target important survival pathways for cancer, announced recent corporate updates and financial results for the fourth quarter and
HOUSTON , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced the company plans to report financial results for the fourth quarter and full year 2018 and provide corporate updates on March 7, 2019 after the close of the U.S.
HOUSTON , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has received an additional $2.6 million disbursement from the Cancer Prevention and Research Institute of Texas (CPRIT).
HOUSTON , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the company has promoted Gail McIntyre , PhD, DABT to chief scientific officer. “Aravive continues to work towards its goal of bringing innovative therapies to
HOUSTON , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) symposium focused on the GAS6-AXL pathway and its role in cancer, as well as the clinical development landscape of
HOUSTON , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun treating patients in the Phase 1b portion of a Phase 1b/Phase 2 trial combining AVB-S6-500 with standard-of-care therapies in patients
HOUSTON , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that company management will participate at the following upcoming investor conference: Event: Piper Jaffray Healthcare Conference Presentation Date & Time: Tuesday,
HOUSTON , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy volunteers. As previously announced, the trial met the safety and tolerability
- Merger completed; now operating as Aravive, Inc. (Nasdaq:ARAV), a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics - FDA Fast Track designation granted for lead candidate, AVB-S6-500 - Initiation of the Phase 1b portion of a Phase
